BrightGene Bio-Medical Technology Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHG:688166
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 205 out of 843
Universe
Global Universe 7586 out of 14642
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
BrightGene Bio-Medical Technology Co., Ltd. |
26
Medium
|
205 out of 843 |
Xenon Pharmaceuticals, Inc. |
27.7
Medium
|
282 out of 843 |
InnoCare Pharma Ltd. |
30.4
High
|
409 out of 843 |
Hugel, Inc. |
34.8
High
|
601 out of 843 |
Protagonist Therapeutics, Inc. |
35.7
High
|
645 out of 843 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
BrightGene Bio-Medical Technology Co., Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
BrightGene Bio-Medical Technology Co., Ltd.'s Management of ESG Material Risk is Average